ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2020
Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Racial and Ethnic Diversity in Clinical Trials for Disease Modifying Drugs in Parkinson Disease: A Systematic Review & Meta-Analysis.Movement disorders clinical practice · 2026Pooled it
- Mechanisms of inequitable access to parkinson's disease care: a critical interpretive synthesis.International journal for equity in health · 2025Pooled it
- Trial Participation in Neurodegenerative Diseases: Barriers and Facilitators: A Systematic Review and Meta-Analysis.Neurology · 2024Pooled it
- Feasibility randomized controlled trial of transcranial direct current stimulation (tDCS) to reduce falls in Parkinson's disease.PM & R : the journal of injury, function, and rehabilitation · 2026Trial
- A randomized safety and feasibility crossover trial of two Mediterranean-ketogenic interventions in individuals with Parkinson's disease.Journal of Parkinson's disease · 2026Trial
- Managing fatigue in Parkinson's disease: Preparing for a randomized controlled trial.Journal of Parkinson's disease · 2025Trial
- Convergent Astrocytic Failure in Parkinson's Disease: A System-Level Model of Pathogenesis and Treatment.Molecular neurobiology · 2026Review
- Implementation of a novel strategy to increase participation of Black and Hispanic people in parkinsonism research.Journal of Parkinson's disease · 2026Article
- A Collaborative Approach to Creating Knowledge-Building Resources for the Early-Stage Parkinson's Disease Community.Neurology and therapy · 2026Article
- Dementia Incidence in Individuals With Parkinson's Disease in the Framingham Heart Study.Annals of clinical and translational neurology · 2026Article
- From past to future: Digital approaches to success of clinical drug trials for Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Feasibility and acceptability of the cross-national multisectoral OPTIM-PARK intervention for people affected with Parkinson's disease and their family carers.BMC health services research · 2026Article
- Feasibility for a Community-Based Parkinson Disease Cohort in Hawaii.Neurology. Clinical practice · 2026Article
- Probiotic supplementation for anxiety symptoms in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial.NPJ Parkinson's disease · 2026Article
- Bridging global diversity gaps in Parkinson disease research.Nature reviews. Neurology · 2026Review
- Article
- Trustworthy AI for medical decisions: Adversarially robust and fair machine learning prediction for Parkinson's disease.PloS one · 2026Article
- Pragmatic trial design enhances diversity and retention among research participants with Lewy body diseases.NPJ dementia · 2026Article
- The patient-centric development of an inclusive multi-arm multi-stage trial for Parkinson's disease.Brain communications · 2026Article
- Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real-World Observational Study (FOSAPO).Movement disorders clinical practice · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Parkinson disease (PD) is highly prevalent among neurodegenerative diseases, affecting a diverse patient population. Despite a general willingness of patients to participate in clinical trials, only a subset of patients enroll in them. Understanding the barriers to trial participation will help to alleviate this discrepancy and improve trial participation. Underrepresented minorities, older patients, and patients with more medical comorbidities in particular are underrepresented in research. In clinical trials, this has the effect of delaying trial completion, exacerbating disparities, and limiting our ability to generalize study results. Efforts to improve trial design and recruitment are necessary to ensure study enrollment reflects the diversity of patients with PD. At the trial design level, broadening inclusion criteria, attending to participant burden, and focusing on trial efficiency may help. At the recruitment stage, increasing awareness, with traditional outreach or digital approaches; improving engagement, particularly with community physicians; and developing targeted recruitment efforts can also help improve enrollment of underrepresented patient groups. The use of technology, for virtual visits, technology-based objective measures, and community engagement, can also reduce participant burden and increase recruitment. By designing trials to consider these barriers to trial participation, we can improve not only the access to research for all our patients but also the quality and generalizability of clinical research in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.